Some opportunities of using xanthine oxidase inhibitors

The review presents modern concepts of the role of xanthine oxidase (XO) in the pathogenesis of a number of diseases. It has been shown that XO activity can be associated with the development and progression not only of gout, but, possibly, diabetes mellitus, hypertension, and other cardiovascular d...

Full description

Saved in:
Bibliographic Details
Main Authors: O. V. Zhelyabina, M. S. Eliseev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2019-03-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/896
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839574177893318656
author O. V. Zhelyabina
M. S. Eliseev
author_facet O. V. Zhelyabina
M. S. Eliseev
author_sort O. V. Zhelyabina
collection DOAJ
description The review presents modern concepts of the role of xanthine oxidase (XO) in the pathogenesis of a number of diseases. It has been shown that XO activity can be associated with the development and progression not only of gout, but, possibly, diabetes mellitus, hypertension, and other cardiovascular diseases.The paradigm of an association of hyperuricemia (HU) with cardiovascular and chronic renal diseases has undergone certain changes — from skepticism to obtaining the evidence of its serious negative impact. Moreover, XO has been established to be a key enzyme involved in the synthesis of uric acid (UA) as a final adenine nucleotides metabolite, and is extensively present in various organs (the liver, intestine, lung, kidneys, heart, and brain) and in plasma. XO plays an important role in the synthesis not only of UA, but also in that of superoxide free radicals. There are two possible mechanisms linking metabolism and inflammation, in which UA is involved: inflammation activated by UA crystallization and generation of superoxide free radicals during its synthesis. The role of reactive oxygen species is discussed in a number of pathological conditions: induction of apoptosis/necrosis, inhibition of expression of many genes, activation of cell signaling cascades, oxidative damage to DNA and lipids, inflammation, metabolic disorders, atherosclerosis, etc. Inhibition of these mechanisms leads to a decrease in the synthesis and accumulation of UA in the bones, joints and other tissues. Accordingly, XO is a confirmed target for the treatment of gout, and, possibly, other HU-associated conditions. After introduction of a new XO inhibitor (iXO) into clinical practice, the target level of UA has can be achieved by more than 80% of patients with gout. So there is a growing interest in the assessment of the potentials of iXO for the treatment of different pathological conditions.
format Article
id doaj-art-df644b7b25e1404fb8c61c1fabf1663e
institution Matheson Library
issn 1996-7012
2310-158X
language Russian
publishDate 2019-03-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj-art-df644b7b25e1404fb8c61c1fabf1663e2025-08-04T14:00:35ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2019-03-0113111412010.14412/1996-7012-2019-1-114-1202157Some opportunities of using xanthine oxidase inhibitorsO. V. Zhelyabina0M. S. Eliseev1V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyThe review presents modern concepts of the role of xanthine oxidase (XO) in the pathogenesis of a number of diseases. It has been shown that XO activity can be associated with the development and progression not only of gout, but, possibly, diabetes mellitus, hypertension, and other cardiovascular diseases.The paradigm of an association of hyperuricemia (HU) with cardiovascular and chronic renal diseases has undergone certain changes — from skepticism to obtaining the evidence of its serious negative impact. Moreover, XO has been established to be a key enzyme involved in the synthesis of uric acid (UA) as a final adenine nucleotides metabolite, and is extensively present in various organs (the liver, intestine, lung, kidneys, heart, and brain) and in plasma. XO plays an important role in the synthesis not only of UA, but also in that of superoxide free radicals. There are two possible mechanisms linking metabolism and inflammation, in which UA is involved: inflammation activated by UA crystallization and generation of superoxide free radicals during its synthesis. The role of reactive oxygen species is discussed in a number of pathological conditions: induction of apoptosis/necrosis, inhibition of expression of many genes, activation of cell signaling cascades, oxidative damage to DNA and lipids, inflammation, metabolic disorders, atherosclerosis, etc. Inhibition of these mechanisms leads to a decrease in the synthesis and accumulation of UA in the bones, joints and other tissues. Accordingly, XO is a confirmed target for the treatment of gout, and, possibly, other HU-associated conditions. After introduction of a new XO inhibitor (iXO) into clinical practice, the target level of UA has can be achieved by more than 80% of patients with gout. So there is a growing interest in the assessment of the potentials of iXO for the treatment of different pathological conditions.https://mrj.ima-press.net/mrj/article/view/896xanthine oxidasereactive oxygen speciesxanthine oxidase inhibitorsxanthine dehydrogenasexanthine oxidoreductasehyperuricemia
spellingShingle O. V. Zhelyabina
M. S. Eliseev
Some opportunities of using xanthine oxidase inhibitors
Современная ревматология
xanthine oxidase
reactive oxygen species
xanthine oxidase inhibitors
xanthine dehydrogenase
xanthine oxidoreductase
hyperuricemia
title Some opportunities of using xanthine oxidase inhibitors
title_full Some opportunities of using xanthine oxidase inhibitors
title_fullStr Some opportunities of using xanthine oxidase inhibitors
title_full_unstemmed Some opportunities of using xanthine oxidase inhibitors
title_short Some opportunities of using xanthine oxidase inhibitors
title_sort some opportunities of using xanthine oxidase inhibitors
topic xanthine oxidase
reactive oxygen species
xanthine oxidase inhibitors
xanthine dehydrogenase
xanthine oxidoreductase
hyperuricemia
url https://mrj.ima-press.net/mrj/article/view/896
work_keys_str_mv AT ovzhelyabina someopportunitiesofusingxanthineoxidaseinhibitors
AT mseliseev someopportunitiesofusingxanthineoxidaseinhibitors